PhinC Development

Your Partner in Quantitative Pharmacology and Modeling

Unlock the power of Modeling & Simulation to drive key decisions in your development process and maximize cost efficiency!

New: Integrated Phase 1 Solutions

Biotech.Boost is a comprehensive suite of services
designed to propel your biotech venture through Phase 1 trials
with efficiency and efficacy.

We understand the unique challenges faced by
biotech startups and offer tailored
solutions to address them.

PhinC guides the key stages of your development
and optimizes its costs.

Integrated modeling for drug development

Optimized strategy, from drug candidate to patient proof of concept

Physiologically-Based Pharmacokinetic modeling

For a better translation from non-clinical to human studies

Population Pharmacokinetics

To quantify and identify the source of variability in a population

Pharmacokinetics NCA

A comprehensive study of the Pharmacokinetics (PK) of your drug candidate

QT / QTc Analysis

A pioneer in exploring cardiac safety in early phase

Integrated Phase 1 Solutions

Tailored solutions to fast-track your biotech Phase 1 trials

Tell us about your project!

Insights from PhinC Development

[Webinar] Translational Mechanistic Modeling : Applications for ADCs

PhinC Development is pleased to host an exclusive webinar dedicated to Translational Mechanistic Modeling: Applications for Antibody Drug Conjugates (ADCs). Discover how Model-Informed Drug Development (MIDD) strategies can accelerate and de-risk ADC programs.

New article: Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation

A first-in-class PBPK model for CLDN18.2-targeted ADCs using PK-Sim® and MoBi®. Read and discover the full article!

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

The FDA is taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.

They trust us

"Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity."

"Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs."

"The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program."